<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548093" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548093/" /><meta name="ncbi_pagename" content="Paclitaxel - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Paclitaxel - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Paclitaxel" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/09/07" /><meta name="citation_pmid" content="31643423" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548093/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Paclitaxel" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/09/07" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548093/" /><meta name="description" content="Paclitaxel is an antineoplastic agent which acts by inhibitor of cellular mitosis and which currently plays a central role in the therapy of ovarian, breast, and lung cancer. Therapy with paclitaxel has been associated with a low rate of serum enzyme elevations, but has not been clearly linked to cases of clinically apparent acute liver injury." /><meta name="og:title" content="Paclitaxel" /><meta name="og:type" content="book" /><meta name="og:description" content="Paclitaxel is an antineoplastic agent which acts by inhibitor of cellular mitosis and which currently plays a central role in the therapy of ovarian, breast, and lung cancer. Therapy with paclitaxel has been associated with a low rate of serum enzyme elevations, but has not been clearly linked to cases of clinically apparent acute liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548093/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Paclitaxel/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548093/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A4F5404679E71000000000413011F.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548093_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548093_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Oxycodone/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Palbociclib/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548093_"><span class="title" itemprop="name">Paclitaxel</span></h1><p class="small">Last Update: <span itemprop="dateModified">September 7, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Paclitaxel.OVERVIEW"><h2 id="_Paclitaxel_OVERVIEW_">OVERVIEW</h2><div id="Paclitaxel.Introduction"><h3>Introduction</h3><p>Paclitaxel is an antineoplastic agent which acts by inhibitor of cellular mitosis and which currently plays a central role in the therapy of ovarian, breast, and lung cancer. Therapy with paclitaxel has been associated with a low rate of serum enzyme elevations, but has not been clearly linked to cases of clinically apparent acute liver injury.</p></div><div id="Paclitaxel.Background"><h3>Background</h3><p>Paclitaxel (pak" li tax' el) is a complex diterpenoid molecule that contains a central 8-member taxane ring. Paclitaxel was initially isolated from the bark of the Western Yew tree (Taxus breviflora) and found to have antitumor activity in high throughput assays. It is a potent antineoplastic agent and its mechanism of action appears to be mediated by its binding to microtubulin, which is important in the mitotic phase of cell division. The binding of paclitaxel prevents the disassembly of the cytoskeletal microtubules, preventing cell division and leading to cell death. Paclitaxel was approved for use in the United States in 1992 and it remains an important agent in the therapy of several cancers. Paclitaxel is considered a first line treatment for advanced ovarian carcinoma and is also used in breast cancer and advanced non-small cell lung cancer and AIDS-related Kaposi's sarcoma. Paclitaxel is available in solution for injection (6 mg/mL) generically and under the brand names Taxol and Onxol. Paclitaxel is also available as protein bound particles in a lyophilized powder for injection under the brand name Abraxane. Paclitaxel is administered intravenously, typically as 3 to 24 hour infusions every three weeks in cycles in combination with other antineoplastic agents. The dose varies by indication and body weight and is reduced in persons with preexisting liver disease. Side effects are common and include diarrhea, nausea, vomiting, mucositis, fatigue, myalgias, skin rash, alopecia, phlebitis, bone marrow suppression, fluid retention, cardiomyopathy, peripheral neuropathy and hypersensitivity reactions. Severe adverse reactions include acute hypersensitivity reactions which occur in up to 2% of patients, typically with the first few infusions, and which are marked by urticaria, rash, fever, facial edema, hypotension, dyspnea and shock which can lead to multiorgan failure and death.</p></div><div id="Paclitaxel.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Paclitaxel has been associated with serum aminotransferase elevations in 7% to 26% of patients, but values greater than 5 times the upper limit of normal (ULN) in only 2% of those receiving the highest doses. Similar rates of alkaline phosphatase elevations and occasional mild bilirubin elevations also occur. The abnormalities are usually asymptomatic, mild and self-limited, rarely requiring dose modification or discontinuation. Paclitaxel has not been linked convincingly to instances of delayed, idiosyncratic clinically apparent liver injury with jaundice. However, the hypersensitivity reactions that occur with infusions of paclitaxel can be severe and accompanied by acute hepatic necrosis. The liver injury may be relatively mild and anicteric (Case 1), but can also be severe with rapid onset of multiorgan failure and death. At least one instance of acute liver failure following a hypersensitivity reaction to paclitaxel has been published in the literature and recent modifications of the product labels for paclitaxel and docetaxel mention the occurrence of toxic deaths following severe infusion reactions. Because paclitaxel is often given with other antineoplastic agents, liver injury arising during therapy cannot always be reliably attributed to paclitaxel rather than to other specific agents. Furthermore, paclitaxel in combination with other anticancer agents may be associated with reactivation of hepatitis B, increased risk of opportunistic viral infections, sinusoidal obstruction syndrome or sepsis, any of which can cause liver test abnormalities or clinically apparent liver injury.</p><p>Likelihood score: D (possible cause of acute hepatic necrosis associated with a hypersensitivity reaction to the initial infusions).</p></div><div id="Paclitaxel.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mild liver injury that arises during therapy is probably due to a direct effect of paclitaxel in inhibiting microtubular function. Paclitaxel is metabolized by the cytochrome P450 system, largely CYP 2C8 and to a lesser extent 3A4. The severe liver injury that accompanies infusion reactions to paclitaxel is likely due to hypersensitivity and acute direct hepatic injury, perhaps due to hypotension and ischemia.</p></div><div id="Paclitaxel.Outcome_and_Management"><h3>Outcome and Management</h3><p>The serum aminotransferase elevations that occur on paclitaxel therapy are usually self-limited and do not require dose modification or discontinuation of therapy. Patients with an acute hypersensitivity reaction to paclitaxel should have the infusion stopped and not be reexposed to paclitaxel or to docetaxel, a closely related taxane (Case 1). The acute hepatic necrosis that accompanies rare instances of hypersensitivity reactions to paclitaxel is usually treated with corticosteroids which may have an effect on the signs and symptoms of hypersensitivity, but may not affect the course of the acute liver injury.</p><p>Drug Class: <a href="/books/n/livertox/AntineoplasticAgents/">Antineoplastic Agents</a>, <a href="/books/n/livertox/Taxanes/">Taxanes</a></p><p>Other Drugs in the Subclass, Taxanes: <a href="/books/n/livertox/Cabazitaxel/">Cabazitaxel</a>, <a href="/books/n/livertox/Docetaxel/">Docetaxel</a></p></div></div><div id="Paclitaxel.CASE_REPORT"><h2 id="_Paclitaxel_CASE_REPORT_">CASE REPORT</h2><div id="Paclitaxel.Case_1_Acute_hepatocellular_i"><h3>Case 1. Acute hepatocellular injury after an infusion of docetaxel.(<a class="bk_pop" href="#Paclitaxel.REF.1">1</a>)</h3><p>A 31 year old woman with endometrial cancer developed abdominal pain and serum aminotransferase elevations the week following an initial infusion of docetaxel and carboplatin. She had no history of liver disease, drug allergies, alcohol abuse or risk factors for viral hepatitis. Her other medical conditions included seasonal allergies, reactive airway disease and dyspepsia. Her endometrial carcinoma was initially treated surgically with hysterectomy and bilateral oophorectomy followed by pelvic irradiation and intravenous cisplatin which was poorly tolerated. She then started paclitaxel and carboplatin but had an immediate hypersensitivity reaction during the infusion manifested by chest tightness with arm and facial flushing despite premedication with antihistamines and dexamethasone. The following week her chemotherapy regimen was switched to docetaxel and carboplatin with intravenous dexamethasone followed by oral dexamethasone. She had mild symptoms of hypersensitivity during the infusions, but during the ensuing week she developed fatigue and abdominal pain. At the time of the next planned infusion, serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> was found to be 649 U/L, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> 211 U/L and alkaline phosphatase 161 U/L (R=11.7: hepatocellular). Serum bilirubin and albumin were normal and INR 0.9. (Table). Therapy was held. The following day, serum ALT levels had decreased. Serologic markers for acute hepatitis A, B and C were negative. Serum ANA was weakly positive (1:80) but SMA and AMA were negative. Imaging of the liver was normal without evidence of biliary or portal venous obstruction. Her symptoms resolved and over the next few weeks her serum aminotransferase levels fell to near normal levels. She was restarted on carboplatin without docetaxel and serum enzymes remained normal or minimally elevated</p><div id="Paclitaxel.Key_Points"><h4>Key Points</h4><div id="Paclitaxel.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548093/table/Paclitaxel.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Paclitaxel.Tc_lrgtbl__"><table><tbody><tr><th id="hd_b_Paclitaxel.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Paclitaxel.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Docetaxel (124 mg iv once)</td></tr><tr><th id="hd_b_Paclitaxel.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Paclitaxel.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hepatocellular (R=11.7)</td></tr><tr><th id="hd_b_Paclitaxel.Tc_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Paclitaxel.Tc_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1+ symptomatic (no jaundice)</td></tr><tr><th id="hd_b_Paclitaxel.Tc_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Paclitaxel.Tc_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 week</td></tr><tr><th id="hd_b_Paclitaxel.Tc_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Paclitaxel.Tc_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 weeks</td></tr><tr><th id="hd_b_Paclitaxel.Tc_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Paclitaxel.Tc_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Carboplatin, dexamethasone</td></tr></tbody></table></div></div></div><div id="Paclitaxel.Laboratory_Values"><h4>Laboratory Values</h4><div id="Paclitaxel.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548093/table/Paclitaxel.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Paclitaxel.Td_lrgtbl__"><table><thead><tr><th id="hd_h_Paclitaxel.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Starting</th><th id="hd_h_Paclitaxel.Td_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Stopping</th><th id="hd_h_Paclitaxel.Td_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a><br />(U/L)</th><th id="hd_h_Paclitaxel.Td_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Alk P<br />(U/L)</th><th id="hd_h_Paclitaxel.Td_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a><br />(mg/dL)</th><th id="hd_h_Paclitaxel.Td_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Paclitaxel.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pre (-2 mo)</td><td headers="hd_h_Paclitaxel.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pre</td><td headers="hd_h_Paclitaxel.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">25</td><td headers="hd_h_Paclitaxel.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">73</td><td headers="hd_h_Paclitaxel.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.2</td><td headers="hd_h_Paclitaxel.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Paclitaxel.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pre (-1 wk)</td><td headers="hd_h_Paclitaxel.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pre</td><td headers="hd_h_Paclitaxel.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">35</td><td headers="hd_h_Paclitaxel.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">66</td><td headers="hd_h_Paclitaxel.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.3</td><td headers="hd_h_Paclitaxel.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Docetaxel and carboplatin</td></tr><tr><td headers="hd_h_Paclitaxel.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 days</td><td headers="hd_h_Paclitaxel.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_Paclitaxel.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">649</td><td headers="hd_h_Paclitaxel.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">161</td><td headers="hd_h_Paclitaxel.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.2</td><td headers="hd_h_Paclitaxel.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Therapy held</td></tr><tr><td headers="hd_h_Paclitaxel.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 days</td><td headers="hd_h_Paclitaxel.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 day</td><td headers="hd_h_Paclitaxel.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">545</td><td headers="hd_h_Paclitaxel.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">148</td><td headers="hd_h_Paclitaxel.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.3</td><td headers="hd_h_Paclitaxel.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INR 0.9</td></tr><tr><td headers="hd_h_Paclitaxel.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14 days</td><td headers="hd_h_Paclitaxel.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 days</td><td headers="hd_h_Paclitaxel.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">295</td><td headers="hd_h_Paclitaxel.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">92</td><td headers="hd_h_Paclitaxel.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.3</td><td headers="hd_h_Paclitaxel.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Paclitaxel.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19 days</td><td headers="hd_h_Paclitaxel.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 days</td><td headers="hd_h_Paclitaxel.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">126</td><td headers="hd_h_Paclitaxel.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">78</td><td headers="hd_h_Paclitaxel.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.2</td><td headers="hd_h_Paclitaxel.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Carboplatin restarted</td></tr><tr><td headers="hd_h_Paclitaxel.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26 days</td><td headers="hd_h_Paclitaxel.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19 days</td><td headers="hd_h_Paclitaxel.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">64</td><td headers="hd_h_Paclitaxel.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">87</td><td headers="hd_h_Paclitaxel.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.3</td><td headers="hd_h_Paclitaxel.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Paclitaxel.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35 days</td><td headers="hd_h_Paclitaxel.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28 days</td><td headers="hd_h_Paclitaxel.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">94</td><td headers="hd_h_Paclitaxel.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">95</td><td headers="hd_h_Paclitaxel.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.3</td><td headers="hd_h_Paclitaxel.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Paclitaxel.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44 days</td><td headers="hd_h_Paclitaxel.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37 days</td><td headers="hd_h_Paclitaxel.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">30</td><td headers="hd_h_Paclitaxel.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">84</td><td headers="hd_h_Paclitaxel.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.2</td><td headers="hd_h_Paclitaxel.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Paclitaxel.Td_1_1_1_1 hd_h_Paclitaxel.Td_1_1_1_2" colspan="2" scope="row" rowspan="1" style="text-align:center;vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Paclitaxel.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;40</b></td><td headers="hd_h_Paclitaxel.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;125</b></td><td headers="hd_h_Paclitaxel.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Paclitaxel.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="Paclitaxel.Comment"><h4>Comment</h4><p>This young woman with endometrial cancer and history of season allergies, had a mild hypersensitivity reaction during an infusion of paclitaxel and significant hepatic injury with a subsequent single infusion of docetaxel. The injury was symptomatic but without jaundice or evidence of hepatic synthetic dysfunction. The rapid rise and equally rapid fall in serum aminotransferase levels suggests direct hepatic injury and acute hepatic necrosis. In this case the injury was mild and self-limited injury, but paclitaxel hypersensitivity reactions can be severe and associated with jaundice and hepatic failure. This patient appeared to have cross sensitivity between paclitaxel and docetaxel.</p></div></div></div><div id="Paclitaxel.PRODUCT_INFORMATION"><h2 id="_Paclitaxel_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Paclitaxel &#x02013; Generic, Onxol&#x000ae;, Taxol&#x000ae;</p><p>Paclitaxel (Powder for Inj.) &#x02013; Generic, Abraxane&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antineoplastic Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Paclitaxel" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Paclitaxel.CHEMICAL_FORMULA_AND_STRUCTUR"><h2 id="_Paclitaxel_CHEMICAL_FORMULA_AND_STRUCTUR_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Paclitaxel.Te" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548093/table/Paclitaxel.Te/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Paclitaxel.Te_lrgtbl__"><table><thead><tr><th id="hd_h_Paclitaxel.Te_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Paclitaxel.Te_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Paclitaxel.Te_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Paclitaxel.Te_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Paclitaxel.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Paclitaxel</td><td headers="hd_h_Paclitaxel.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134998291" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">33069-62-4</a></td><td headers="hd_h_Paclitaxel.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C47-H51-N-O14</td><td headers="hd_h_Paclitaxel.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134998291" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134998291" alt="image 134998291 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="Paclitaxel.CITED_REFERENCE"><h2 id="_Paclitaxel_CITED_REFERENCE_">CITED REFERENCE</h2><dl class="temp-labeled-list"><dt>1.</dt><dd><div class="bk_ref" id="Paclitaxel.REF.1">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network.  Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]</div></dd></dl></div><div id="Paclitaxel.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Paclitaxel_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 07 September 2020</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Paclitaxel.REF.zimmerman.1999">Zimmerman HJ. Hepatotoxic effects of oncotherapeutic and immunosuppressive agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp.673-708.<div><i>(Textbook of hepatotoxicity published in 1999; paclitaxel is not mentioned).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.deleve.2013">DeLeve LD. Cancer chemotherapy. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 549-68.<div><i>(Review of hepatotoxicity of cancer chemotherapeutic agents; the taxanes are not specifically discussed).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.wellstein.2018">Wellstein A, Giaccone G, Atkins MB, Sausille EA. Taxanes. Cytotoxic agents. Chemotherapy of neoplastic diseases. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1187-9.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.onetto.1993.131">Onetto N, Canetta R, Winograd B, Catane R, Dougan M, Grechko J, Burroughs J, Rozencweig M. Overview of Taxol safety. <span><span class="ref-journal">J Natl Cancer Inst Monogr. </span>1993;(15):131–9.</span> [<a href="/pubmed/7912519" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7912519</span></a>]<div><i>(Among 655 patients treated with paclitaxel, dose limiting toxicities included bone marrow suppression [especially neutropenia], mucositis, neuropathy and rarely cardiomyopathy; hypersensitivity reactions can be controlled with premedication; liver test abnormalities were dose dependent with any AST elevations in 7-26% of patients and values &#x0003e;5 times ULN in only 2% of those receiving the highest dose).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.rowinsky.1993.1">Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). <span><span class="ref-journal">Semin Oncol. </span>1993;<span class="ref-vol">20</span>(4) Suppl 3:1–15.</span> [<a href="/pubmed/8102012" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8102012</span></a>]<div><i>(Extensive review of toxicities of paclitaxel; according to data on file with the sponsor, elevations of AST, Alk P and bilirubin &#x0003e;5 times the ULN occurred in &#x0003c;1% of 402 patients in phase II and III trials).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.horikoshi.1994.2407">Horikoshi N, Inoue K, Aiba K, Mukaiyama T, Ogihara A, Sumida T, Akatsuka Y, et al.  <span><span class="ref-journal">Gan To Kagaku Ryoho. </span>1994;<span class="ref-vol">21</span>:2407–14.</span> [Phase I study of paclitaxel] Japanese. [<a href="/pubmed/7944484" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7944484</span></a>]</div></li><li><div class="bk_ref" id="Paclitaxel.REF.von_hoff.1997.s13">Von Hoff DD. The taxoids: same roots, different drugs. <span><span class="ref-journal">Semin Oncol. </span>1997;<span class="ref-vol">24</span>(4) Suppl 13:S13–3.</span> [<a href="/pubmed/9335511" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9335511</span></a>]<div><i>(Review of the development of paclitaxel and docetaxel, clinical use, efficacy and toxicity stressing the differences between the two taxoids, which are due largely to differences in pharmacokinetics).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.fumoleau.1997.s19">Fumoleau P. Efficacy and safety of docetaxel in clinical trials. <span><span class="ref-journal">Am J Health Syst Pharm. </span>1997;<span class="ref-vol">54</span>(24) Suppl 2:S19–24.</span> [<a href="/pubmed/9435929" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9435929</span></a>]<div><i>(Overall response rates to docetaxel and paclitaxel in advanced breast cancer ranged from 29-68% of patients; major dose related toxicities included neutropenia, mucositis, cardiomyopathy and fluid retention; hepatotoxicity was not mentioned).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.colomer.2000.20">Colomer R, Llombart A, Lluch A, Ojeda B, Barnadas A, Carana V, Fernandez Y, et al.  Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial. <span><span class="ref-journal">Semin Oncol. </span>2000;<span class="ref-vol">27</span>(1) Suppl 2:20–4.</span> [<a href="/pubmed/10697032" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10697032</span></a>]<div><i>(Among 43 women with metastatic breast cancer treated with paclitaxel and gemcitabine for up to 8 cycles, 41% had serum aminotransferase elevations which were above 5 times ULN in 5%).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.de_pas.2000.821">De Pas T, de Braud F, Danesi R, Sessa C, Catania C, Curigliano G, Fogli S, et al.  Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naive patients with advanced non-small-cell lung cancer. <span><span class="ref-journal">Ann Oncol. </span>2000;<span class="ref-vol">11</span>:821–7.</span> [<a href="/pubmed/10997809" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10997809</span></a>]<div><i>(Among 35 patients with lung cancer given escalating doses of gemcitabine and paclitaxel, 33% of first and 20% of all cycles were associated with aminotransferase elevations &#x0003e;5 times ULN, but all were asymptomatic and reversible, although some led to dose reduction).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.patnaik.2000.3677">Patnaik A, Warner E, Michael M, Egorin MJ, Moore MJ, Siu LL, Fracasso PM, et al.  Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. <span><span class="ref-journal">J Clin Oncol. </span>2000;<span class="ref-vol">18</span>:3677–89.</span> [<a href="/pubmed/11054441" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11054441</span></a>]<div><i>(Among 58 patients with advanced cancers treated with cycles of paclitaxel, carboplatin and valspodar, 3 had aminotransferase elevations &#x0003e;5 times ULN, two of which were dose limiting).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.douillard.2001.1179">Douillard JY, Lerouge D, Monnier A, Bennouna J, Haller AM, Sun XS, Assouline D, et al.  Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study. <span><span class="ref-journal">Br J Cancer. </span>2001;<span class="ref-vol">84</span>:1179–84.</span> [<a href="/pmc/articles/PMC2363882/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2363882</span></a>] [<a href="/pubmed/11336467" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11336467</span></a>]<div><i>(Among 54 patients with advanced lung cancer treated with cycles of paclitaxel and gemcitabine, 98% had some elevation in liver tests and 9% had ALT elevations of &#x0003e;5 times ULN, but all were asymptomatic and self-limited).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.markman.2003.34">Markman M, Zanotti K, Webster K, Belinson J, Rose P. Toxicity associated with carboplatin/paclitaxel/Irinotecan use in advanced ovarian cancer: preliminary analysis. <span><span class="ref-journal">Oncology (Williston Park). </span>2003;<span class="ref-vol">17</span>(5) Suppl 5:34–5.</span> [<a href="/pubmed/12800604" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12800604</span></a>]<div><i>(Among 26 women with advanced ovarian cancer given paclitaxel, carboplatin and irinotecan, 1[4%] developed transient ALT elevations &#x0003e;5 times ULN).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.harries.2004.1651">Harries M, O'Donnell A, Scurr M, Reade S, Cole C, Judson I, Greystoke A, et al.  Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours. <span><span class="ref-journal">Br J Cancer. </span>2004;<span class="ref-vol">91</span>:1651–5.</span> [<a href="/pmc/articles/PMC2410023/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2410023</span></a>] [<a href="/pubmed/15494716" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15494716</span></a>]<div><i>(Among 15 patients with advanced solid cancers given carboplatin and paclitaxel conjugated to fatty acids, 5 [33%] developed transient ALT elevations &#x0003e;5 times ULN).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.ohlmann.2007.1425">Ohlmann CH, Kohlmorgen S, Sahi D, Engelmann U, Heidenreich A. <span><span class="ref-journal">Urologe A. </span>2007;<span class="ref-vol">46</span>:1425–7.</span> [Lethal course after chemotherapy with docetaxel. Acute liver failure with accompanying erythema multiforme major] German. [<a href="/pubmed/17563866" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17563866</span></a>]<div><i>(67 year old man with prostate cancer developed Stevens-Johnson Syndrome, neutropenia and thrombocytopenia after 5 weekly infusions of docetaxel, with subsequent rise in liver tests and jaundice that progressed to hepatic failure and death; few details provided).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.bailey.2007.3623">Bailey HH, Alberti DB, Thomas JP, Mulkerin DL, Binger KA, Gottardis MM, Martell RE, et al.  Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors. <span><span class="ref-journal">Clin Cancer Res. </span>2007;<span class="ref-vol">13</span>:3623–9.</span> [<a href="/pubmed/17510207" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17510207</span></a>]<div><i>(Among 26 patients with advanced cancer treated with paclitaxel and an experimental farnesyl transferase inhibitor, 3 developed febrile neutropenia and raised ALT levels 1 to 3 days after the infusions, not attributed to paclitaxel).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.pignata.2008.229">Pignata S, Breda E, Scambia G, Pisano C, Zagonel V, Lorusso D, Greggi S, et al.  A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. <span><span class="ref-journal">Crit Rev Oncol Hematol. </span>2008;<span class="ref-vol">66</span>:229–36.</span> [<a href="/pubmed/18243011" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18243011</span></a>]<div><i>(Among 27 elderly women with advanced ovarian cancer treated with weekly infusions of carboplatin and paclitaxel, one had ALT increase above 5 times ULN during first course, but without jaundice, and she subsequently tolerated 5 more courses).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.campone.2009.315">Campone M, Levy V, Bourbouloux E, Berton Rigaud D, Bootle D, Dutreix C, Zoellner U, et al.  Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. <span><span class="ref-journal">Br J Cancer. </span>2009;<span class="ref-vol">100</span>:315–21.</span> [<a href="/pmc/articles/PMC2634724/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2634724</span></a>] [<a href="/pubmed/19127256" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19127256</span></a>]<div><i>(Among 16 patients with advanced malignancies treated with paclitaxel and oral everolimus, one developed transient ALT elevations &#x0003e;5 times ULN).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.sun.2009.237">Sun Q, Liu C, Zhong H, Zhong B, Xu H, Shen W, Wang D. Multi-center phase II trial of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric and gastro-esophageal cancer. <span><span class="ref-journal">Jpn J Clin Oncol. </span>2009;<span class="ref-vol">39</span>:237–43.</span> [<a href="/pubmed/19264768" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19264768</span></a>]<div><i>(Among 49 patients with gastrointestinal cancers treated with cyclic regimens of paclitaxel and cisplatin, 9 [18%] developed transient ALT elevations which were greater than 5 times ULN in 1 [2%], but none had jaundice).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.oshita.2010.66">Oshita F, Saito H, Murakami S, Kondo T, Yamada K. Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer. <span><span class="ref-journal">Am J Clin Oncol. </span>2010;<span class="ref-vol">33</span>:66–9.</span> [<a href="/pubmed/19786849" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19786849</span></a>]<div><i>(Among 16 patients with advanced non-small cell lung cancer treated with paclitaxel, irinotecan and gefitinib, 8 had ALT elevations [only one &#x0003e;5 times ULN], but none developed jaundice).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.mandaliya.2015.825603">Mandaliya H, Baghi P, Prawira A, George MK. A rare case of paclitaxel and/or trastuzumab induced acute hepatic necrosis. <span><span class="ref-journal">Case Rep Oncol Med. </span>2015;<span class="ref-vol">2015</span>:825603. </span> [<a href="/pmc/articles/PMC4641929/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4641929</span></a>] [<a href="/pubmed/26605100" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26605100</span></a>]<div><i>(62 year old woman with metastatic breast cancer received 4 cycles of doxorubicin and cyclophosphamide and developed pulmonary edema and respiratory failure within 12 hours of the initial infusions of paclitaxel and trastuzumab, dying one day later and autopsy showing acute hepatic necrosis; no liver test results provided).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network.  Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 49 [5.5%] were attributed to antineoplastic agents of which only 1 was due to a taxane [docetaxel]).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.fushida.2016.2353">Fushida S, Kinoshita J, Kaji M, Oyama K, Hirono Y, Tsukada T, Fujimura T, et al.  Paclitaxel plus valproic acid versus paclitaxel alone as second- or third-line therapy for advanced gastric cancer: a randomized Phase II trial. <span><span class="ref-journal">Drug Des Devel Ther. </span>2016;<span class="ref-vol">10</span>:2353–8.</span> [<a href="/pmc/articles/PMC4966651/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4966651</span></a>] [<a href="/pubmed/27524882" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27524882</span></a>]<div><i>(Among 66 patients with advanced gastric cancer treated with paclitaxel with or without valproic acid, overall and progression free survival was similar in the two groups; one patient had acute liver injury, but no details provided).</i></div></div></li><li><div class="bk_ref" id="Paclitaxel.REF.k_mmel.2017.1">K&#x000fc;mmel S, Paepke S, Huober J, Schem C, Untch M, Blohmer JU, Eiermann W, et al.  Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). <span><span class="ref-journal">Eur J Cancer. </span>2017;<span class="ref-vol">84</span>:1–8.</span> [<a href="/pubmed/28768217" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28768217</span></a>]<div><i>(Among 333 women with breast cancer given neoadjuvant therapy with cabazitaxel [every 3 weeks] or paclitaxel [weekly] for 12 weeks before definitive surgery, pathologic complete responses were lower with cabazitaxel [1% vs 11%] while serious adverse events were higher [25% vs 10%], ALT elevations occurring at similar rates [40% vs 45%] which were above 5 times ULN in only 1.2% vs 0.6%).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548093</span><span class="label">PMID: <a href="/pubmed/31643423" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643423</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Oxycodone/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Palbociclib/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548093&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548093/?report=reader">PubReader</a></li><li><a href="/books/NBK548093/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548093" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548093" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Paclitaxel. [Updated 2020 Sep 7].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548093/pdf/Bookshelf_NBK548093.pdf">PDF version of this page</a> (118K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(Paclitaxel/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Paclitaxel: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Paclitaxel" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Paclitaxel: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4866234" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4866234" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4866234" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31644104" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Taxanes</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Taxanes<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31644206" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Docetaxel</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Docetaxel<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643890" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gemcitabine</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gemcitabine<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643851" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Cabazitaxel</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Cabazitaxel<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643875" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Trastuzumab and Ado-Trastuzumab Emtansine</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Trastuzumab and Ado-Trastuzumab Emtansine<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643423" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643423" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60468da4ddcb804c591cfa74">Paclitaxel - LiverTox</a><div class="ralinkpop offscreen_noflow">Paclitaxel - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T15:48:37-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal103&amp;ncbi_phid=CE8A4F5404679E71000000000413011F&amp;ncbi_session=CE8A4F540468DA31_1043SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548093%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548093&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548093/&amp;ncbi_pagename=Paclitaxel - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A4F540468DA31_1043SID /projects/books/PBooks@9.2 portal103 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>